| URL | https://www.fiercepharma.com/manufacturing/merck-s |
| Source | Fierce Pharma |
| Date Published | 03/03/2021 |
| Author Name | Fraiser Kansteiner |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 268.8 |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | covid-19 vaccine |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Under-utilized capacity, essential product, Biden |
| Government Incentive dollar amount: | BARDA $268.8 million |